Ventavis-Studie
Open-label, uncontrolled, prospective long-term observation of Ventavis inhalation therapy in the treatment of patients with primary pulmonary hypertension up to 4 years

BAY 63-2521 / IMP 12166
A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with pulmonary hypertension in a 12-week 3 times a day individual dose titration scheme
 
SERAPHIN-Studie
AC-055-302 Study with Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to improve clinical outcome
AC-055-303 OL Study with an ERA in Pulmonary arterial Hypertension to improve clinical outcome (Open Label)
 
BAY 63-2521 / IMP 12916
A multi center, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with interstitial lung disease associated pulmonary hypertension
 
TRANSFORMS-Extension

A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferion ß-1a (Avonex®) administered i.m. once weekly in patients with relapsind-remitting multiple sclerosis (Extensionsstudie)
 
VOLT-Studie
A Post-Marketing Observational Surveillance Program for Ambrisentan

A multicenter, randomized, double blind, placebo-controlled, two-arm study to assess the efficacy and safety of oral BAY 63-2521 in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent or persisting pulmonary hypertension after surgical treatment
 
BAY 63-2521 / IMP 11349
Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg TID) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
 
DETECT AC-052-510
A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension
 

BAY 63-2521 / IMP 12934
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)
 
BAY 63-2521 / IMP 12935
Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)
 
Lungenfunktionsprüfungen
A 76-week prospective, open-label, multicenter study to evaluate the long-term effect Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson's disease
 

IMPRES-Extension-Studie
An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES Extension
 
CTEPH-Studie
Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
 
FREEDOM-OL 
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension
 

PROGRESS-CAP-Studie
Prospektive, längsschnittliche, multizentrische Fall-Kohorten-Studie zur Progression der ambulant erworbenen Pneumonie
 
GRIPHON-Studie
A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension

GRIPHON OL Studie
Long-term single-arm open-label study, to assess the safety and tolerability of ACT-293987 in patients with pulmonary arterial hypertension
 
BAY 63-2521 / 15096
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2 and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension

PAH Biomarker
Korrelation von Biomarkern zur Hämodynamik, Belastbarkeit und Schweregradklassifizierung bei pulmonal arterieller Hypertonie und chronisch thromboembolischer Hypertonie

AMB112565
A randomized, multicenter study of first-line Ambrisentan and Tadalafil combination therapy in subjects with pulmonary arterial hypertension

CAMN107X2201
A 24 week, randomized, double blind, multicenter, placebocontrolled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in pulmonary arterial hypertension

CIGMA Study
A randomized, double-blind, placebo-controlled, multicenter, parallelgroup, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in severe community acquired pneumonia (sCAP)

COMPERA-XL
Prospective registry of newly initiated therapies for pulmonary hypertension

DACH Smoking in PH
Smoking: a risk factor for pulmonary arterial hypertension? A multicentre and multinational case-control study

REM-PH-416
A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin Therapy in Subjects with Pulmonary Arterial Hypertension